BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38702652)

  • 1. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of thyroid hormone supplementation after thyroid lobectomy.
    Lee DY; Seok J; Jeong WJ; Ahn SH
    J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Na YM; Cho JS; Park MH
    Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
    Xia Q; Dong S; Bian PD; Wang J; Li CJ
    Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
    Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
    Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy.
    Ito M; Miyauchi A; Morita S; Kudo T; Nishihara E; Kihara M; Takamura Y; Ito Y; Kobayashi K; Miya A; Kubota S; Amino N
    Eur J Endocrinol; 2012 Sep; 167(3):373-8. PubMed ID: 22711760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
    Dou Y; Chen Y; Hu D; Su X
    Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
    Sugitani I; Fujimoto Y
    Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
    Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
    Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
    Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
    Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
    Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
    Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The magnitude of increased Levothyroxine dose during pregnancy in patients on thyroid-stimulating hormone (TSH) suppression treatment after total thyroidectomy for papillary carcinoma.
    Minakata M; Ito M; Kishi T; Hada M; Masaki Y; Nakamura T; Kousaka K; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
    Endocr J; 2022 Feb; 69(2):165-172. PubMed ID: 34526424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients.
    Ito M; Miyauchi A; Hisakado M; Yoshioka W; Kudo T; Nishihara E; Kihara M; Ito Y; Miya A; Fukata S; Nishikawa M; Nakamura H
    Endocr J; 2019 Nov; 66(11):953-960. PubMed ID: 31270299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
    Xiao L; Wu J; Jiang L; Xu Y; Liu B
    Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients.
    Ito M; Miyauchi A; Kang S; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nakamura H; Amino N
    Eur J Endocrinol; 2015 Sep; 173(3):333-40. PubMed ID: 26077156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined prognostic value of preoperative serum thyrotrophin and thyroid hormone concentration in papillary thyroid cancer.
    Liu Y; Huang Y; Mo G; Zhou T; Hou Q; Shi C; Yu J; Lv Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24503. PubMed ID: 35666615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.